These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 15867390)

  • 21. Elevated ERK1/ERK2/estrogen receptor cross-talk enhances estrogen-mediated signaling during long-term estrogen deprivation.
    Martin LA; Farmer I; Johnston SR; Ali S; Dowsett M
    Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S75-84. PubMed ID: 16113101
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells.
    Pietras RJ; Arboleda J; Reese DM; Wongvipat N; Pegram MD; Ramos L; Gorman CM; Parker MG; Sliwkowski MX; Slamon DJ
    Oncogene; 1995 Jun; 10(12):2435-46. PubMed ID: 7784095
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Akt activation by estrogen in estrogen receptor-negative breast cancer cells.
    Tsai EM; Wang SC; Lee JN; Hung MC
    Cancer Res; 2001 Dec; 61(23):8390-2. PubMed ID: 11731414
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CCAAT/Enhancer binding protein delta (c/EBPdelta) regulation and expression in human mammary epithelial cells: I. "Loss of function" alterations in the c/EBPdelta growth inhibitory pathway in breast cancer cell lines.
    Sivko GS; DeWille JW
    J Cell Biochem; 2004 Nov; 93(4):830-43. PubMed ID: 15389879
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Upregulation of AIB1, aromatase and ERα provides long-term estrogen-deprived human breast cancer cells with a mechanistic growth advantage for survival.
    Tilghman SL; Sabnis G; Brodie AM
    Horm Mol Biol Clin Investig; 2010 Dec; 3(1):357-66. PubMed ID: 25961207
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ErbB (HER) receptors can abrogate antiestrogen action in human breast cancer by multiple signaling mechanisms.
    Kurokawa H; Arteaga CL
    Clin Cancer Res; 2003 Jan; 9(1 Pt 2):511S-5S. PubMed ID: 12538508
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Both autocrine and paracrine effects of transfected acidic fibroblast growth factor are involved in the estrogen-independent and antiestrogen-resistant growth of MCF-7 breast cancer cells.
    Zhang L; Kharbanda S; Hanfelt J; Kern FG
    Cancer Res; 1998 Jan; 58(2):352-61. PubMed ID: 9443417
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Functional interaction of fibroblast growth factor-8, bone morphogenetic protein and estrogen receptor in breast cancer cell proliferation.
    Masuda H; Otsuka F; Matsumoto Y; Takano M; Miyoshi T; Inagaki K; Shien T; Taira N; Makino H; Doihara H
    Mol Cell Endocrinol; 2011 Aug; 343(1-2):7-17. PubMed ID: 21664418
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Involvement of Ras activation in human breast cancer cell signaling, invasion, and anoikis.
    Eckert LB; Repasky GA; Ulkü AS; McFall A; Zhou H; Sartor CI; Der CJ
    Cancer Res; 2004 Jul; 64(13):4585-92. PubMed ID: 15231670
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Up-regulation of PI3K/Akt signaling by 17beta-estradiol through activation of estrogen receptor-alpha, but not estrogen receptor-beta, and stimulates cell growth in breast cancer cells.
    Lee YR; Park J; Yu HN; Kim JS; Youn HJ; Jung SH
    Biochem Biophys Res Commun; 2005 Nov; 336(4):1221-6. PubMed ID: 16169518
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A role for Akt in mediating the estrogenic functions of epidermal growth factor and insulin-like growth factor I.
    Martin MB; Franke TF; Stoica GE; Chambon P; Katzenellenbogen BS; Stoica BA; McLemore MS; Olivo SE; Stoica A
    Endocrinology; 2000 Dec; 141(12):4503-11. PubMed ID: 11108261
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapeutic observations in MCF-7 aromatase xenografts.
    Brodie A; Jelovac D; Macedo L; Sabnis G; Tilghman S; Goloubeva O
    Clin Cancer Res; 2005 Jan; 11(2 Pt 2):884s-8s. PubMed ID: 15701882
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Post-transcriptional regulation of chemokine receptor CXCR4 by estrogen in HER2 overexpressing, estrogen receptor-positive breast cancer cells.
    Sengupta S; Schiff R; Katzenellenbogen BS
    Breast Cancer Res Treat; 2009 Sep; 117(2):243-51. PubMed ID: 18807177
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Activation of mitogen-activated protein kinase in xenografts and cells during prolonged treatment with aromatase inhibitor letrozole.
    Jelovac D; Sabnis G; Long BJ; Macedo L; Goloubeva OG; Brodie AM
    Cancer Res; 2005 Jun; 65(12):5380-9. PubMed ID: 15958587
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dietary genistein negates the inhibitory effect of letrozole on the growth of aromatase-expressing estrogen-dependent human breast cancer cells (MCF-7Ca) in vivo.
    Ju YH; Doerge DR; Woodling KA; Hartman JA; Kwak J; Helferich WG
    Carcinogenesis; 2008 Nov; 29(11):2162-8. PubMed ID: 18632754
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Upregulation of AIB1, aromatase and ERα provides long-term estrogen-deprived human breast cancer cells with a mechanistic growth advantage for survival.
    Tilghman SL; Sabnis G; Brodie AM
    Horm Mol Biol Clin Investig; 2011 Jan; 3(1):357-366. PubMed ID: 23606920
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MCF-7 breast cancer cells overexpressing transfected c-erbB-2 have an in vitro growth advantage in estrogen-depleted conditions and reduced estrogen-dependence and tamoxifen-sensitivity in vivo.
    Liu Y; el-Ashry D; Chen D; Ding IY; Kern FG
    Breast Cancer Res Treat; 1995 May; 34(2):97-117. PubMed ID: 7647336
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Functional implications of altered subcellular localization of PELP1 in breast cancer cells.
    Vadlamudi RK; Manavathi B; Balasenthil S; Nair SS; Yang Z; Sahin AA; Kumar R
    Cancer Res; 2005 Sep; 65(17):7724-32. PubMed ID: 16140940
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The steroidal antiestrogen ICI 182,780 is an inhibitor of cellular aromatase activity.
    Long BJ; Tilghman SL; Yue W; Thiantanawat A; Grigoryev DN; Brodie AM
    J Steroid Biochem Mol Biol; 1998 Nov; 67(4):293-304. PubMed ID: 9883986
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cyr61 promotes breast tumorigenesis and cancer progression.
    Tsai MS; Bogart DF; Castañeda JM; Li P; Lupu R
    Oncogene; 2002 Nov; 21(53):8178-85. PubMed ID: 12444554
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.